Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy

[Display omitted] •Kaplan-Meier–estimated 1-year retention on lacosamide (LCM) was high (80%).•≥12-month seizure freedom was 29.9 %/24.4 % in focal-onset/generalized seizure population.•>75 % clinicians/caregivers reported improvements in patients during LCM treatment.•Long-term adjunctive LCM (median exposure: 679 days) was generally well tolerated.•Behavior and executive functioning were generally stable during long-term LCM treatment. To evaluate long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide (LCM) treatment in pediatric patients (≥1 month to 75 % of patients by both physicians and caregivers. Treatment-emergent adverse events (T